Mendelian randomization shows GLP-1 drugs may reduce diabetic retinopathy risk by 41% | Research

The takeaway

Mendelian randomization analysis found GLP-1 receptor agonists significantly reduce diabetic retinopathy risk (OR 0.59, 95% CI 0.39-0.89), supported by systematic review showing lower DR incidence versus insulin therapy.

41% lower DR risk
Mendelian randomization provides genetic evidence that GLP-1 drugs causally reduce diabetic retinopathy risk, beyond glucose control effects

What the researchers found

MR: OR 0.59 (95% CI 0.39-0.89, p=0.011); SMR: OR 0.48 (95% CI 0.27-0.86, p=0.013). Systematic review: GLP-1RA reduced DR incidence vs insulin therapy. Results from discovery and validation (FinnGen) cohorts combined via meta-analysis.

Why it matters

Diabetic retinopathy is a leading cause of blindness. If GLP-1 drugs protect against it beyond just glucose control, this adds an important reason to prescribe them for diabetic patients, especially those at risk for eye complications.

How the study worked

Two-sample Mendelian randomization using 9 cis-eQTL SNPs as genetic instruments, with SMR validation. Discovery cohort from GWAS catalog + FinnGen validation. Plus systematic review of 3 cohort studies.

What this study cannot tell us

European populations only. Limited to genetic proxy—does not capture dose-response. Only 3 studies in systematic review. Inconsistent results vs non-insulin agents.

How to read the evidence

Mendelian randomization provides stronger causal inference than observational studies. Two validation methods (MR + SMR) converge. Supported by clinical systematic review.

When this study was published

Published in 2025.

The bigger picture

MR provides causal inference that observational studies cannot. The finding suggests GLP-1 drugs have direct protective effects on retinal vasculature beyond glucose lowering, aligning with known anti-inflammatory and vascular protective properties of GLP-1.

Questions still open

What retinal mechanisms mediate GLP-1 protection against diabetic retinopathy?
Does the protective effect apply to non-European populations?
Should diabetic retinopathy risk factor into GLP-1 drug selection for T2DM?

Common questions

Do GLP-1 drugs protect eyesight in diabetics?

This genetic study suggests yes—GLP-1 drugs may reduce the risk of diabetic retinopathy (eye damage from diabetes) by about 41%. Clinical studies also support lower rates of eye problems with GLP-1 drugs compared to insulin therapy.

What is Mendelian randomization and why does it matter?

MR uses natural genetic variations as a kind of natural experiment to test whether a drug truly causes an effect. Because genetics are assigned at birth, they are not affected by the biases that plague regular observational studies. This makes the finding of GLP-1 eye protection more convincing than typical observational data.

Read the original research

Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations.

Diabetology & metabolic syndrome, 17(1), 345

View on PubMed ↗Publisher’s paper ↗

Citation

Shen, Baixuan; Wang, Wanying; Guo, Yuanhui; Chen, Zilong; Liu, Chuanxin; Huang, Jiarui; Li, Ying. (2025). Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations.. Diabetology & metabolic syndrome, 17(1), 345. https://doi.org/10.1186/s13098-025-01878-3